Based on in vitro studies and xenograft models, STAT3 is considered to play a tumour-promoting role in EGFR mutant NSCLC13, 14, 16, 18, therefore, inhibition of STAT3 is considered as therapeutic intervention in lung ACs46. The gene discussed is EGFR; the disease is neoplasm.